FY2030 Earnings Forecast for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Annexon in a research report issued to clients and investors on Thursday, April 2nd. HC Wainwright analyst A. Ghosh forecasts that the company will earn $0.43 per share for the year. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

A number of other brokerages have also recently issued reports on ANNX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Finally, Chardan Capital restated a “buy” rating and issued a $16.00 price target on shares of Annexon in a report on Friday, March 20th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Annexon Stock Performance

ANNX stock opened at $5.50 on Friday. The company’s 50-day moving average price is $5.52 and its 200 day moving average price is $4.59. Annexon has a 52 week low of $1.28 and a 52 week high of $7.18. The company has a market cap of $882.59 million, a P/E ratio of -4.04 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Insiders Place Their Bets

In other Annexon news, Director William H. Carson acquired 8,000 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were purchased at an average cost of $5.67 per share, with a total value of $45,360.00. Following the purchase, the director owned 62,405 shares in the company, valued at approximately $353,836.35. The trade was a 14.70% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Michael Overdorf sold 6,225 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $31,747.50. Following the completion of the sale, the executive vice president directly owned 124,464 shares in the company, valued at approximately $634,766.40. The trade was a 4.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 32,513 shares of company stock worth $165,973. 11.87% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ANNX. CIBC Bancorp USA Inc. acquired a new position in shares of Annexon during the 3rd quarter worth approximately $31,000. Engineers Gate Manager LP acquired a new stake in Annexon during the 2nd quarter valued at $32,000. SG Americas Securities LLC purchased a new position in Annexon during the third quarter worth $34,000. Mirae Asset Global Investments Co. Ltd. increased its position in Annexon by 65.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after buying an additional 2,785 shares in the last quarter. Finally, Savant Capital LLC acquired a new position in shares of Annexon in the third quarter worth $40,000.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.